FIELD: pharmaceutics.
SUBSTANCE: group of inventions discloses a dosage form of a medicine for inducing specific immune response to HIV virus surface glycoprotein gp120 as an active substance containing a mixture of artificial recombinant polypeptide produced in E. coli microorganism and having the following amino acid sequence: MATEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEVVLSCNTSVITQACPKVSFEPIPIHYCAPAGFAILKCNNKTFNGTGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSVNFTDNAKTIIVQLNTSVEINCTHCNISRAKWNNTLKQIASKLREQFGNNKTIIFKQSSGGDPEIVTHSFNCGGEFFYCNSTQLFNSTWFNSTWSTEGSNNTEGSDTITLPCRIKQIINMWQKVGKAMYAPPISGQIRCSSNITGLLLTRDGGNSNNESEIFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPTKAKLDPNSSSVDKLAAALEHHHHHH, enclosed together with the plasmid DNA, in the liposomes consisting of a mixture of mannosylated dipalmitoyl phosphatidyl ethanolamine, 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine containing lactose as a cryoprotector and alpha-tocopherol as an antioxidant, as well as its preparation method.
EFFECT: medicine according to the group of inventions is efficient in inducing specific immune response to HIV virus surface glycoprotein gp120, as well as has higher stability during its storage and after its recovery in a polar solvent.
2 cl, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNOPROPHYLACTIC VACCINE AGAINST HIV BASED ON HIV-SPECIFIC ANTIBODIES | 2008 |
|
RU2505604C2 |
| VACCINE AGAINST HIV/AIDS | 2010 |
|
RU2475264C2 |
| RECOMBINANT CHIMERICAL nTBI POLYPEPTIDE-IMMUNOGEN WITH ABILITY TO INDUCE NEUTRALIZING ANTIBODIES TO TYPE 1 HUMAN IMMUNODEFICIENCY VIRUS AND INTENDED FOR USE AS COMPONENT OF VACCINE AGAINST HIV-1 | 2016 |
|
RU2642258C1 |
| RAPID SELECTION METHOD FOR HIV GP-120 VARIANTS | 2012 |
|
RU2603732C2 |
| ARTIFICIAL YkuJ-MPER GENE ENCODING YkuJ-MPER RECOMBINANT PROTEIN-IMMUNOGEN, pET21a-YkuJ-MPER RECOMBINANT PLASMID DNA, PROVIDING EXPRESSION OF ARTIFICIAL YkuJ-MPER GENE, AND YkuJ-MPER RECOMBINANT PROTEIN-IMMUNOGEN, WHICH IS CARRIER OF MEMBRANE-PROXIMAL AREA OF HIV-1 AND INTENDED FOR INDUCTION IN BROADLY NEUTRALIZING ANTIBODIES | 2017 |
|
RU2679076C1 |
| RECOMBINANT PLASMID DNA PTBI-HBSAG COMPRISING CHIMERIC GENE TBI-HBSAG UNDER CONTROL OF SMALLPOX VACCINE PROMOTER P7,5K AND STRAIN OF RECOMBINANT SMALLPOX VACCINE INDUCING IMMUNE RESPONSE AGAINST HIV AND HUMAN HEPATITIS B IN ANIMAL BODY | 2001 |
|
RU2194075C2 |
| IMMUNOGENIC COMPOSITION AND METHOD OF FUSED PROTEIN VACCINE DEVELOPMENT | 2004 |
|
RU2407749C2 |
| SYSTEMS FOR EXPRESSION OF NEWCASTLE DISEASE VIRUS RECOMBINANT RNA AND VACCINES | 1999 |
|
RU2270864C2 |
| GENETIC CONSTRUCT FOR GENE EXPRESSION mNG_CD4-CXCR4, RECOMBINANT PLASMID rVSV_MNG_CD4-CXCR4 AND A RECOMBINANT VESICULAR STOMATITIS VIRUS STRAIN rVSV_mNG_CD4-CXCR4, WHICH PROVIDES TARGETED VIROLYSIS OF CELLS EXPOSING HIV-1 GP120/GP41 PROTEINS TROPISM X4 ON THEIR SURFACE | 2021 |
|
RU2768032C1 |
| RECOMBINANT VACCINE AGAINST HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 | 2006 |
|
RU2317107C2 |
